Frontiers in Pharmacology最新文献

{"title":"Corrigendum: Role of β-interferon inducer (DEAE-Dextran) in tumorigenesis by VEGF and NOTCH1 inhibition along with apoptosis induction.","authors":"Anita K Bakrania, Bhavesh C Variya, Snehal S Patel","doi":"10.3389/fphar.2024.1433625","DOIUrl":"https://doi.org/10.3389/fphar.2024.1433625","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fphar.2017.00930.].</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1433625"},"PeriodicalIF":4.4,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142902639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma calcitonin gene-related peptide and nitric oxide predict therapeutic response to amlodipine in pediatric primary hypertension.","authors":"Hui Wang, Yao Lin, Yuting Wang, Chen Shen, Yaqi Li, Yang Liu, Lin Shi","doi":"10.3389/fphar.2024.1425863","DOIUrl":"10.3389/fphar.2024.1425863","url":null,"abstract":"<p><strong>Background: </strong>There is a lack of suitable predictive markers for assessing the efficacy of amlodipine in treating children with primary hypertension. This study aimed to explore whether plasma calcitonin gene-related peptide (CGRP) and nitric oxide (NO) could predict the effectiveness of amlodipine in pediatric primary hypertension.</p><p><strong>Methods: </strong>This study enrolled 74 children and adolescents with primary hypertension who were prescribed amlodipine monotherapy, and after 4 weeks of treatment, they were divided into responders and non-responders according to blood pressure. Baseline data differences between the two groups were analyzed, followed by binary logistic regression to assess the correlation between significant variables and therapeutic efficacy. The receiver operating characteristic curve was used to evaluate the predictive efficacy, and the nomogram model was established to predict therapeutic response to amlodipine.</p><p><strong>Results: </strong>The responders exhibited lower body mass index, C-peptide and plasma CGRP levels, and higher NO levels compared to the non-responders (<i>p</i> < 0.05). Multivariable logistic analysis revealed that plasma CGRP and NO were independently associated with the therapeutic response to amlodipine, showing a higher predictive performance when used in combination (AUC: 0.814, 95% CI 0.714-0.914) with a predictive sensitivity of 86.5% and specificity of 70.1%. The nomogram model displayed good calibration, and the decision curve analysis indicated this model led to net benefits in a wide range of threshold probability.</p><p><strong>Conclusion: </strong>CGRP and NO may be valuable biomarkers for predicting amlodipine effectiveness in the treatment of pediatric primary hypertension, while the nomogram model indicates excellent predictive value.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1425863"},"PeriodicalIF":4.4,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142902760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacology and mechanisms of apigenin in preventing osteoporosis.","authors":"Sun Lin, Wang Yincang, Du Jiazhe, Xu Xilin, Xiaofeng Zhang","doi":"10.3389/fphar.2024.1486646","DOIUrl":"10.3389/fphar.2024.1486646","url":null,"abstract":"<p><p>Osteoporosis (OP) stands as the most prevalent systemic skeletal condition associated with aging. The current clinical management of OP predominantly depends on anti-resorptive and anabolic agents. Nevertheless, prolonged use of some of these medications has been observed to reduce efficacy and elevate adverse effects. Given the necessity for sustained or even lifelong treatment of OP, the identification of drugs that are not only effective but also safe and cost-efficient is of utmost significance. As disease treatment paradigms continue to evolve and recent advancements in OP research come to light, certain plant-derived compounds have emerged, presenting notable benefits in the management of OP. This review primarily explores the pharmacological properties of apigenin and elucidates its therapeutic mechanisms in the context of OP. The insights provided herein aspire to offer a foundation for the judicious use of apigenin in forthcoming research, particularly within the scope of OP.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1486646"},"PeriodicalIF":4.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting intra-abdominal candidiasis in elderly septic patients using machine learning based on lymphocyte subtyping: a prospective cohort study.","authors":"Jiahui Zhang, Guoyu Zhao, Xianli Lei, Na Cui","doi":"10.3389/fphar.2024.1486346","DOIUrl":"10.3389/fphar.2024.1486346","url":null,"abstract":"<p><strong>Objective: </strong>Intra-abdominal candidiasis (IAC) is difficult to predict in elderly septic patients with intra-abdominal infection (IAI). This study aimed to develop and validate a nomogram based on lymphocyte subtyping and clinical factors for the early and rapid prediction of IAC in elderly septic patients.</p><p><strong>Methods: </strong>A prospective cohort study of 284 consecutive elderly patients diagnosed with sepsis and IAI was performed. We assessed the clinical characteristics and parameters of lymphocyte subtyping at the onset of IAI. A machine-learning random forest model was used to select important variables, and multivariate logistic regression was used to analyze the factors influencing IAC. A nomogram model was constructed, and the discrimination, calibration, and clinical effectiveness of the model were verified.</p><p><strong>Results: </strong>According to the results of the random forest and multivariate analyses, gastrointestinal perforation, renal replacement therapy (RRT), T-cell count, CD28+CD8+ T-cell count and CD38+CD8+ T-cell count were independent predictors of IAC. Using the above parameters to establish a nomogram, the area under the curve (AUC) values of the nomogram in the training and testing cohorts were 0.840 (95% CI 0.778-0.902) and 0.783 (95% CI 0.682-0.883), respectively. The AUC in the training cohort was greater than the <i>Candida</i> score [0.840 (95% CI 0.778-0.902) vs. 0.539 (95% CI 0.464-0.615), p< 0.001]. The calibration curve showed good predictive values and observed values of the nomogram; the DCA results showed that the nomogram had high clinical value.</p><p><strong>Conclusion: </strong>We established a nomogram based on the T-cell count, CD28+CD8+ T-cell count, CD38+CD8+ T-cell count and clinical risk factors that can help clinical physicians quickly rule out IAC or identify elderly patients at greater risk for IAC at the onset of infection.</p><p><strong>Clinical trial registration: </strong>[chictr.org.cn], identifier [ChiCTR2300069020].</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1486346"},"PeriodicalIF":4.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimized automated radiosynthesis of ¹⁸F-JNJ64413739 for purinergic ion channel receptor 7 (P2X7R) imaging in osteoporotic model rats.","authors":"Yingtong Lu, Yan Cui, Lu Hou, Yuanfang Jiang, Jingjie Shang, Lu Wang, Hao Xu, Weijian Ye, Yang Qiu, Bin Guo","doi":"10.3389/fphar.2024.1517127","DOIUrl":"10.3389/fphar.2024.1517127","url":null,"abstract":"<p><strong>Objective: </strong>To optimize the automated radiosynthesis of the purinergic ion channel receptor 7 (P2X7R) imaging agent ¹⁸F-JNJ64413739 and evaluate its potential for brain imaging in osteoporotic model rats.</p><p><strong>Methods: </strong>A more electron-deficient nitropyridine was employed as the labeling precursor to facilitate the ¹⁸F-labeling. The radiosynthesis was conducted on an AllinOne synthesis module, and followed by purification via high-performance liquid chromatography (HPLC). The resulting ¹⁸F-JNJ64413739 was subjected to quality control tests. Small-animal PET/CT imaging studies were performed in sham and osteoporotic model rats.</p><p><strong>Results: </strong>The optimized automated radiossynthesis of ¹⁸F-JNJ64413739 was successfully completed in approximately 100 min with non-decay-corrected radiochemical yield of 6.7% ± 3.8% (n = 3), >97% radiochemical purity and >14.3 ± 1.3 GBq/μmol molar activity. The product met all clinical quality requirements. ¹⁸F-JNJ64413739 PET/CT imaging showed revealed significantly higher radioactivity uptake in various brain regions of the osteoporotic model rats compared to sham control group.</p><p><strong>Conclusion: </strong>We successfully optimized the automated radiosynthesis of ¹⁸F-JNJ64413739. The resulting tracer not only met clinical quality requirements but also demonstrated potential for clinical application in the diagnosis of osteoporosis, as evidenced by higher radioactivity uptake in various brain regions of osteoporotic model rats compared to normal controls.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1517127"},"PeriodicalIF":4.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JiangyaTongluo decoction ameliorates tubulointerstitial fibrosis via regulating the SIRT1/PGC-1α/mitophagy axis in hypertensive nephropathy.","authors":"Yun Zhao, Qi Jia, Gaimei Hao, Lin Han, Yushan Gao, Xiaoyu Zhang, Ziming Yan, Boyang Li, Yiping Wu, Boya Zhang, Yubo Li, Jianguo Qin","doi":"10.3389/fphar.2024.1491315","DOIUrl":"10.3389/fphar.2024.1491315","url":null,"abstract":"<p><strong>Introduction: </strong>With the increasing prevalence of hypertension, the incidence of kidney diseases is also increasing, resulting in a serious public burden. Jiangya Tongluo decoction (JYTL), a recognized prescription in traditional Chinese medicine (TCM), is commonly used to calm an overactive liver and reduce excess yang, while also promoting blood flow to alleviate obstructions in the meridians. Previous research has indicated that JYTL may help mitigate kidney damage caused by hypertension; however, the underlying mechanisms have not been thoroughly assessed.</p><p><strong>Methods: </strong>First, an amalgamation of UPLC-QE/MS and network pharmacology techniques was employed to pinpoint potential active components, primary targets, and crucial action mechanisms of JYTL in treating hypertensive nephropathy (HN). Then, we used spontaneous hypertensive rats (SHRs) and Wistar-Kyoto rats (WKYs) to evaluate the efficacy of JYTL on HN with valsartan as a positive reference. We also conducted DCFH-DA fluorescence staining in rat renal tissues to detect the level of ROS. Western blotting and immunohistochemistry were performed to investigate further the effect of JYTL decoction on key targets and signaling pathways.</p><p><strong>Results: </strong>Through UPLC-QE/MS and network analysis, 189 active ingredients and 5 hub targets were identified from JYTL. GSEA in the MitoCarta3.0 database and PPI network analysis revealed that JYTL predominantly engages in the Sirt1-mitophagy signaling pathway. Tanshinone iia, quercetin, and adenosine in JYTL are the main active ingredients for treating HN. <i>In vivo</i> validation showed that JYTL decoction could improve kidney function, ameliorate tubulointerstitial fibrosis (TIF), and improve mitochondrial function by inhibiting ROS production and regulating mitochondrial dynamics in SHRs. JYTL treatment could also increase the expression of SIRT1, PGC-1α, Nrf1, and TFAM, and activate PINK1/Parkin-mediated mitophagy.</p><p><strong>Conclusion: </strong>JYTL decoction may exert renal function protective and anti-fibrosis effects in HN by ameliorating mitochondrial function and regulating the SIRT1/PGC-1α-mitophagy pathway.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1491315"},"PeriodicalIF":4.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The advent of chimeric antigen receptor T Cell therapy in recalibrating immune balance for rheumatic autoimmune disease treatment.","authors":"Qianyu Guo, Jie Li, Juanjuan Wang, Linxin Li, Jia Wei, Liyun Zhang","doi":"10.3389/fphar.2024.1502298","DOIUrl":"10.3389/fphar.2024.1502298","url":null,"abstract":"<p><p>CAR-T cell therapy, a cutting-edge cellular immunotherapy with demonstrated efficacy in treating hematologic malignancies, also exhibits significant promise for addressing autoimmune diseases. This innovative therapeutic approach holds promise for achieving long-term remission in autoimmune diseases, potentially offering significant benefits to affected patients. Current targets under investigation for the treatment of these conditions include CD19, CD20, and BCMA, among others. However, CAR-T therapy faces difficulties such as time-consuming cell manufacturing, complex and expensive process, and the possibility of severe adverse reactions complicating the treatment, etc. This article examines CAR-T therapy across various rheumatic autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SS), systemic sclerosis (SSc), antisynthetase syndrome (ASS), and ANCA-associated vasculitis (AAV), highlighting both therapeutic advancements and ongoing challenges.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1502298"},"PeriodicalIF":4.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142902768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling.","authors":"Qian Huang, Rui Xiao, Jing Lu, Yao Zhang, Liang Xu, Jie Gao, Jing Sun, Haiping Wang","doi":"10.3389/fphar.2024.1532797","DOIUrl":"https://doi.org/10.3389/fphar.2024.1532797","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fphar.2022.973182.].</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1532797"},"PeriodicalIF":4.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brg1 and RUNX1 synergy in regulating TRPM4 channel in mouse cardiomyocytes.","authors":"Tao Ban, Xianhui Dong, Ziyue Ma, Jing Jin, Jing Li, Yunfeng Cui, Yuyang Fu, Yongzhen Wang, Yadong Xue, Tingting Tong, Kai Zhang, Yuxuan Han, Meimei Shen, Yu Zhao, Ling Zhao, Lingzhao Xiong, Hongzhao Lv, Yang Liu, Rong Huo","doi":"10.3389/fphar.2024.1494205","DOIUrl":"10.3389/fphar.2024.1494205","url":null,"abstract":"<p><strong>Background: </strong>Transient Receptor Potential Melastatin 4 (TRPM4), a non-selective cation channel, plays a critical role in cardiac conduction abnormalities. Brg1, an ATP-dependent chromatin remodeler, is essential for regulating gene expression in both heart development and disease. Our previous studies demonstrated Brg1 impacted on cardiac sodium/potassium channels and electrophysiological stability, its influence on TRPM4 expression and function remained unexplored.</p><p><strong>Methods: </strong>We investigated the role of Brg1 in regulating TRPM4 expression and function through overexpression and knockdown experiments in mouse cardiomyocytes and TRPM4-overexpressing HEK293 cells by western blot, qPCR, immunofluorescence staining and patch clamp techniques. Cardiomyocytes were exposed to hypoxia for 12 h to mimic cardiac stress, and Brg1 inhibition was performed to assess its impact on TRPM4 under hypoxia. Bioinformatic analyses (STRING and JASPAR databases), Co-immunoprecipitation (Co-IP), dual luciferase reporter assays, and Chromatin Immunoprecipitation (ChIP) were employed to study the interaction between Brg1, RUNX1, and TRPM4 transcription regulation.</p><p><strong>Results: </strong>Brg1 positively regulated TRPM4 expression in mouse cardiomyocytes and modulated TRPM4 current in TRPM4-overexpressing HEK293 cells. Brg1 inhibition markedly diminishes TRPM4's hyperexpression in cardiomyocytes exposed to hypoxia. Integrative analyses utilizing STRNG databases and Protein Data Bank unveiled a putative interaction between Brg1 and the transcription factor RUNX1, and we substantiated the interaction between Brg1 and RUNX1. Several binding sites of RUNX1 with the TRPM4 promoter region were predicted by the JASPAR database, and empirical validation substantiated Brg1 modulated TRPM4 promoter activity via RUNX1 engagement. ChIP confirmed that Brg1 interacted with RUNX1 forming a transcriptional complex that located in TRPM4 promoter.</p><p><strong>Conclusion: </strong>Our study demonstrated that Brg1 and RUNX1 formed a transcriptional complex that modulated TRPM4 expression and function, especially under hypoxic conditions. These findings provided new insights into TRPM4 regulation and highlighted its potential as a therapeutic target for cardiac hypoxia-related disorders.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1494205"},"PeriodicalIF":4.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macranthoidin B restrains the epithelial-mesenchymal transition through COX-2/PGE₂ pathway in endometriosis.","authors":"Yi Ding, Xiaoqian Yang, Qinghua Wei, Xuanming Bi, Yuxin Zhang, Yuxia Ma, Meisen Yang, Xiaoyu Xu, Cong Li, Qin Wang, Yi Chen","doi":"10.3389/fphar.2024.1492098","DOIUrl":"10.3389/fphar.2024.1492098","url":null,"abstract":"<p><strong>Introduction: </strong>Macranthoidin B is one of the primary and unique triterpenoid saponin metabolites from <i>Lonicera macranthoides</i> Hand. -Mazz, which is used to treat endometriosis (EMS) in traditional Chinese medicine. However, the effect of macranthoidin B remains unknown in EMS. This study aimed to elucidate the effect and mechanism of macranthoidin B in EMS.</p><p><strong>Methods: </strong>Using rat autograft EMS model, the volume of ectopic endothelium, the histopathology, serum E₂ and PROG were evaluated after macranthoidin B's treatment. In primary endometriotic stromal and HEC1-B cells, the invasion and metastasis were assessed by scratch wound and Transwell tests. The epithelial-mesenchymal transition and COX-2/PGE₂ pathway were examined <i>in vivo</i> and <i>in vitro</i>. Macranthoidin B were combined with LPS or celecoxib.</p><p><strong>Results: </strong>In a rat autograft EMS model, macranthoidin B suppressed ectopic lesion volume, improved histopathological morphology, and regulated serum estradiol (E2) and progesterone (PROG) levels. Additionally, macranthoidin B inhibited invasion and metastasis of primary endometriotic stromal cells and HEC1-B cells. Mechanistically, macranthoidin B suppressed COX-2/PGE₂ pathway and epithelial-mesenchymal transition both <i>in vivo</i> and <i>in vitro</i>. LPS, the COX-2/PGE2 pathway activator, showed the promotion of epithelial-mesenchymal transition, invasion and metastasis. Macranthoidin B exhibited the antagonistic effects against LPS. Celecoxib, the COX-2/PGE2 pathway inhibitor, restrained the epithelial-mesenchymal transition, invasion and metastasis. This effect of celecoxib was enhanced by macranthoidin B.</p><p><strong>Discussion: </strong>Macranthoidin B prevents epithelial-mesenchymal transition through COX-2/PGE2 pathway in EMS. It will facilitate the macranthoidin B's development and broaden its potential application.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1492098"},"PeriodicalIF":4.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}